VERSION 1 -REVIEW

REVIEWER
Maire O'Dwyer School of Pharmacy and Phamaceutical Sciences Trinity College Dublin Ireland REVIEW RETURNED 13-Aug-2019
GENERAL COMMENTS
Thank you the authors for the submission of a protocol for this interesting study. Please see the following suggested revisions below: Introduction: reference to the influence of family history on osteoporosis could be included Introduction: Please outline the aims and specific objectives more clearly Methods: Sampling: Please outline why the age of 20 was chosen. Please outline how capacity to consent will be determined? Controls: Please outline if any matching will take place between the cases and controls Psychiatric assessments: Please include who will apply these instruments? A health care professional or a researcher? Socio-demographics: I would consider the inclusion of family history of osteoporosis here Study integrity: Please add more detail about data protection and how study data will be protected and accessed securely. Sample size: please provide a reference and more detail as to how this sample size was arrived at Dissemination: Are there plans to disseminate the findings back to patients who partook in the study?
REVIEWER
Micol Rothman University of Colorado School of Medicine
REVIEW RETURNED
30-Aug-2019
GENERAL COMMENTS
This is an interesting idea for a study, however, I don't think a protocol for a small case control study is worthy of publication. This will be several hundred people and not powered for fracture data. The results will be interesting to see, but I don't see a reason to publish the protocol ahead of time. Also a few concerns on the protocol itself --Blood being collected: Is the only blood collected what is listed on page 21? I would imagine there will be lithium use and may want to assess Ca/PTH/urine Ca? --No mention of testosterone or estradiol?.
-Perhaps bone quality could be assessed with TBS rather than calcaneal US
REVIEWER
Ulrich Schweiger Universität zu Lübeck, Germany REVIEW RETURNED 10-Nov-2019
GENERAL COMMENTS
This is an excellent and important study proposal written by experts in the subject. I have two small concerns 1) Using data from the Geelong osteoporosis study means that some of the comparison data may have been collected approximately. How do the authors ascertain that there are no factors that result in a bias. I think about things like altered programming of the DXA machines or altered reference ranges in laboratory data.
2) (Compared to unipolar depression) the rate of disease episodes may be stronger influenced by the use of antidepressants (antidepressive-induced mania) or use of stimulants.Will there be efforts to discriminate between mania or hypomania with or without a probable induction by substances?
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 -Introduction: reference to the influence of family history on osteoporosis could be included -Introduction: Please outline the aims and specific objectives more clearly
We have now included family history as a potential risk factor in the introduction and the refined aims.
Amendments to the text read as follows:
"These include lifestyle factors such as smoking, alcohol, diet and habitual physical activity, socioeconomic status, family history, prescription drug use especially psychotropic agents, medical and psychiatric comorbidity and biomarkers of common risk, such as systemic inflammatory and oxidative stress markers." (page 5)
"Specially, we aim to assess: 1. the association between bipolar disorder and parameters of bone health including bone mineral density, bone quality and markers of bone turnover 2. whether relationships are explained by specific biological, lifestyle and social factors" (page 5) -Sampling: Please outline why the age of 20 was chosen An age of 20+ was chosen to match the age of our control participants.
-Please outline how capacity to consent will be determined?
Competency to give consent is based on clinical judgement of the study personal. An inability to provide written informed consent is an exclusion criterion of the study.
-Controls: Please outline if any matching will take place between the cases and controls
Matching will occur through statistical modelling.
-Psychiatric assessments: Please include who will apply these instruments? A health care professional or a researcher?
All clinical interviews will be conducted by trained personnel with postgraduate qualifications in psychology, under the supervision of a clinically trained psychologist.
"All clinical interviews will be conducted by trained personnel with postgraduate qualifications in psychology, under the supervision of a clinically trained psychologist" (page 7)
-Socio-demographics: I would consider the inclusion of family history of osteoporosis here
For the participants to date, we have not collected this information.
-Study integrity: Please add more detail about data protection and how study data will be protected and accessed securely This information has now been included.
"Data are stored on the mainframe computer of Barwon Health in password protected databases that are backed up daily from the file server. Entry of new data is being performed daily, enabling the maintenance of a current, up-to-date database." (page 12) -Sample size: please provide a reference and more detail as to how this sample size was arrived at.
To our knowledge there have been no previous studies investigating bipolar disorder and bone mineral density (BMD). The 7% difference was based on our previous work that reported a mean BMD difference of 7% between individuals with and without depressive symptoms (Jacka, 2004) .
"The statistical analysis will compare data for cases and controls. Based on a power of 80%, statistical significance at the 0.05 level and our previous work (ref), calculations suggest we require 200 cases to detect a difference of 7% in BMD at the femoral neck." (page 12) -Dissemination: Are there plans to disseminate the findings back to patients who partook in the study?
A summary of findings will be provided to participants on completion of the study.
Additionally, a summary of findings will be provided to participants on completion of the study." (page 12)
Reviewer: 2 -Blood being collected: Is the only blood collected what is listed on page 21? I would imagine there will be lithium use and may want to assess Ca/PTH/urine Ca? -No mention of testosterone or oestradiol? -Perhaps bone quality could be assessed with TBS rather than calcaneal US
A morning blood sample is collected following an overnight fast and stored at -80˚C for batch analyses. We have listed the planned analyses; markers of bone turnover, inflammation and oxidative stress. The above suggestions are all possible but subject to further funding. Happy to include a sentence regarding future analyses if requested.
Reviewer 3 -Using data from the Geelong osteoporosis study means that some of the comparison data may have been collected approximately. How do the authors ascertain that there are no factors that result in a bias. I think about things like altered programming of the DXA machines or altered reference ranges in laboratory data.
Male and female control participants will be drawn from the most recent follow-up phases of the GOS, which have been undertaken within the same period as for the data collection for the cases. Stored blood samples for both the cases and controls will be sent for batch analyses at the completion of the study.
-(Compared to unipolar depression) the rate of disease episodes may be stronger influenced by the use of antidepressants (antidepressive-induced mania) or use of stimulants. Will there be efforts to discriminate between mania or hypomania with or without a probable induction by substances?
Cases are required to be euthymic at the time of study assessment, denoted by a score of <16 on the Bipolar Depression Rating Scale and <14 on the Young Mania Rating Scale. This has been included on page 8.
